Axicabtagene ciloleucel is indicated for adult patients with certain types of blood cancers:

Large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
Relapsed or refractory follicular lymphoma after two or more lines of systemic therapy (under accelerated approval).

It is intended for patients whose disease has not responded to or has returned after standard treatments. It is not used as a first-line therapy and is not indicated for patients with primary central nervous system lymphoma.

axicabtagene ciloleucel

Common brand names

Approved use in